Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer by licensing an early-stage candidate from Kumquat Biosciences. The deal – which has a total value of up to ...

A Chinese biotech helmed by an AstraZeneca veteran has secured $108 million in series B funds, which the company will use to advance its lead KRAS inhibitor into phase 3 studies. D3 Bio saw previous ...

Select the journal/section where you want your idea to be submitted: Cancer immunology research has increasingly focused on the complex interactions between oncogenic drivers, such as KRAS mutations, ...